test

Ryan Cappelli

@Prosight Management, Lp

Latest period2024 - Q3ReportedManaged Assets$406.357MTotal holdings45
Assets growth rate21.46%Assets growth rate (2-Q avg)7.27%Continuous growth in asset value1 quarters

Portfolio positions

This chart displays the top 10 holdings in Prosight Management, Lp's 2024 - Q3 portfolio, based on their 13F SEC filing, out of a total of 45 positions.

Assets under management

The assets under management (AUM) of Prosight Management, Lp over the past 10 years (40 quarters) show continuous growth in total asset value over the last 1 quarters. As of the latest 13F SEC filing for 2024 - Q3, they manage 406.357M in assets, with a quarterly growth rate of 21.46% and a 2-quarter average growth rate of 7.27%. The portfolio is managed by Ryan Cappelli, and others.

Portfolio holdings

CurrentNew PositionIncreasedDecreasedExited
InvestmentPortfolio %Reported Value
NBIXNeurocrine Biosciences Inc
Recent Activity
Increased 129.63%
1.76%
$7.144M
62,000 shares@ $115.22 avg price
4642⤦Ishares Tr
Recent Activity
New Position
1.58%
$6.406M↓ Put
29,000 shares@ $220.89 avg price
ERASErasca Inc
Recent Activity
Decreased -27.85%
1.34%
$5.416M
1.984M shares@ $2.73 avg price
HAEHaemonetics Corp Mass
Recent Activity
New Position
1.29%
$5.225M
65,000 shares@ $80.38 avg price
LIVNLivanova Plc
Recent Activity
New Position
1.17%
$4.729M
90,000 shares@ $52.54 avg price
COGTCogent Biosciences Inc
Recent Activity
Decreased -17.83%
1.1%
$4.437M
410,830 shares@ $10.8 avg price
1481⤦Cassava Sciences Inc
Recent Activity
New Position
1.08%
$4.382M↓ Put
148,900 shares@ $29.43 avg price
BPMCBlueprint Medicines Corp
Recent Activity
New Position
1.08%
$4.357M
47,100 shares@ $92.5 avg price
TECXTectonic Therapeutic Inc
Recent Activity
Increased 104%
1.03%
$4.17M
137,614 shares@ $30.3 avg price
CTMXCytomx Therapeutics Inc
Recent Activity
New Position
0.88%
$3.566M
3.022M shares@ $1.19 avg price